feed,title,long_url,short_url
Benzinga,InflaRx's Vilobelimab Hits Primary Endpoint Goal In Late-Stage ANCA-Associated Vasculitis Study,https://benzinga.com/general/biotech/21/05/21077368/inflarxs-vilobelimab-hits-primary-endpoint-goal-in-late-stage-anca-associated-vasculitis-study,https://j.mp/3hh4JN7
